FDA Approves Niraparib for Frontine Maintenance of Advanced Ovarian Cancer

On April 29, 2020, the U.S. Food and Drug Administration approved niraparib (Zejula, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

Read the FDA announcement.

Posted 4/29/2020